Surinabant

From WikiMD's WELLNESSPEDIA

Surinabant


Surinabant is a selective antagonist of the CB1 receptor and was researched as a potential treatment for nicotine addiction and obesity. It was developed by Sanofi-Aventis but its development was discontinued in 2011.

History[edit]

Sanofi-Aventis, a global pharmaceutical company, developed Surinabant with the aim of treating conditions such as nicotine addiction and obesity. The development of Surinabant was part of a wider trend in the pharmaceutical industry to explore the therapeutic potential of cannabinoid receptor antagonists. However, the development of Surinabant was discontinued in 2011.

Pharmacology[edit]

Surinabant is a selective antagonist of the CB1 receptor, which is one of the two main receptors in the endocannabinoid system. The CB1 receptor is primarily located in the brain and is involved in a variety of physiological processes, including appetite regulation and the addictive properties of nicotine. By blocking the CB1 receptor, Surinabant was intended to reduce appetite and decrease the rewarding effects of nicotine.

Clinical Trials[edit]

Surinabant underwent several clinical trials to assess its safety and efficacy. However, the results of these trials were mixed. Some studies suggested that Surinabant could reduce the rewarding effects of nicotine and decrease appetite. However, other studies found that Surinabant had little effect on appetite and did not significantly reduce nicotine cravings. In addition, some participants in the trials reported experiencing adverse side effects, including depression and anxiety.

Discontinuation[edit]

The development of Surinabant was discontinued in 2011. This decision was made in light of the mixed results from the clinical trials and the reported side effects. The discontinuation of Surinabant was part of a wider trend in the pharmaceutical industry, with several other companies also discontinuing their development of CB1 receptor antagonists around the same time.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Surinabant&oldid=5369166"